Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
It was the tweet heard around the biotech world, again. Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price... Read more »
[Updated, 1:09 pm ET, see below] Heather and Jessica Tomko will tell you that they’re nothing alike. They’ve got different interests, different tastes in movies, television, and music. If... Read more »
Pfizer has just won the sweepstakes for San Francisco Bay Area cancer drugmaker Medivation, with a buyout made official early Monday morning.
Cerulean Pharma survived a near-death experience once before. But the Waltham, MA-based company now has another crisis on its hands.
It wasn’t too long ago that the gene editing system CRISPR-Cas9 was just a tool for research labs, not companies developing drugs. But that’s all changed, and now it’s on companies... Read more »
The ink is barely dry on Pfizer’s agreement to buy Bind Therapeutics out of bankruptcy and shut it down, but the employee exodus has begun.
Andrew Hirsch, who was Cambridge, MA-based... Read more »
It wasn’t too long ago that OncoGenex Pharmaceuticals had high hopes that a drug called custirsen might make a big impact on the fast-moving treatment landscape for prostate cancer. A couple... Read more »
The wait continues. An FDA ruling on a Duchenne muscular dystrophy drug from Sarepta Therapeutics—which could be the first ever approved for the disease—has been imminent for a while now, yet... Read more »
Tyler Jacks is a cancer research pioneer, one of the co-chairs of the White House’s ambitious Cancer “Moonshot” initiative, and has helped advise a number of companies developing cancer drugs... Read more »
Step by step, a small biotech called Aldeyra Therapeutics has been trying to build a case for a new type of inflammation-fighting medicine. Data released this morning by the Lexington, MA-based... Read more »
The option-to-buy deal, in biotech, is a way to hedge a bet. A big firm will pay a fee for the right to acquire a smaller company later on, with the... Read more »
Over the past few years, Bristol-Myers Squibb and Merck have brought to market two rival immunotherapy drugs, so-called checkpoint inhibitors, that have begun to change the way certain cancers are treated.... Read more »
Biogen was once again all over the biotech newswire this week. First came a positive surprise; data that could set the stage for the first-ever drug approved for spinal muscular atrophy,... Read more »
When Shire bought Baxalta earlier this year, one of the programs it inherited was a treatment that, at one point, was the leader in an emerging race to treat hemophilia with... Read more »
Spinal muscular atrophy affects over 25,000 people in the U.S. and stops many of them from ever being able to walk. Yet scientists’ understanding of the underlying genetic cause of SMA... Read more »
Seres Therapeutics raised $134 million in an IPO and made history in the process, becoming the first drug developer targeting the microbiome to go public in the U.S. But disappointing news... Read more »
This week’s World Federation of Hemophilia World Congress in Orlando, FL, where researchers gathered to present the latest updates in treatments for the chronic bleeding disorder, marked the latest step in... Read more »
[Updated, 2:30 p.m. ET, see below] It’s not uncommon for a biotech’s larger partner to make a buyout offer for its smaller counterpart. But unfortunately for Bind Therapeutics, that... Read more »
After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring from the Indianapolis pharma giant.... Read more »
October 27, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.